Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy

Purpose There is an ongoing controversial debate about the effectiveness of laser treatments in chronic central serous chorioretinopathy (cCSC). We performed a prospective non-randomized interventional study to learn about the effects of a subthreshold laser treatment (Topcon Endpoint Management™, T...

Full description

Saved in:
Bibliographic Details
Published in:Graefe's archive for clinical and experimental ophthalmology 2021-11, Vol.259 (11), p.3271-3281
Main Authors: Schworm, Benedikt, Siedlecki, Jakob, Keidel, Leonie F., Herold, Tina R., Luft, Nikolaus, Priglinger, Siegfried G.
Format: Article
Language:English
Subjects:
Acuity
Adult
Aged
Central Serous Chorioretinopathy - diagnosis
Central Serous Chorioretinopathy - drug therapy
Central Serous Chorioretinopathy - surgery
Chronic Disease
Fluorescein Angiography
Humans
Laser Therapy
Lasers
Medicine
Medicine & Public Health
Middle Aged
Ophthalmology
Patients
Photochemotherapy
Photodynamic therapy
Prospective Studies
Retinal Disorders
Tomography, Optical Coherence
Treatment Outcome
Visual Acuity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose There is an ongoing controversial debate about the effectiveness of laser treatments in chronic central serous chorioretinopathy (cCSC). We performed a prospective non-randomized interventional study to learn about the effects of a subthreshold laser treatment (Topcon Endpoint Management™, Topcon Healthcare Inc., Tokyo, Japan) in patients with cCSC. Methods Patients with cCSC and a minimum symptom duration of 4 months were included and treated with a standardized laser pattern covering the macular area. Retreatment was performed every 3 months if persistent subretinal fluid was observed. The primary endpoint was resolution of subretinal fluid at 6 months. Further outcome parameters included best corrected visual acuity, microperimetry, central macular and subfoveal choroidal thickness. Results A total of 42 eyes of 39 patients were included. Mean patient age was 48 ± 10.6 years (range 25–67). Mean symptomatic time before inclusion into the study was 134 ± 133.4 weeks (16–518). Before inclusion, 78.6% of the patients had failed to resolve subretinal fluid under mineralocorticoid receptor antagonists and 14.3% had a recurrence after half-dose photodynamic therapy. Complete resolution of subretinal fluid was observed in 42.9% at 6 months and in 53.8% at 12 months after baseline. Central retinal thickness decreased from 398 ± 135 µm to 291 ± 68 µm (p 
ISSN:0721-832X
1435-702X
DOI:10.1007/s00417-021-05256-3